- CRISPR Technology Where it Stands and What the Future HoldsPosted 1 day ago
- Ask the Expert – Using Luminex Technology to Non-Invasively Monitor Stem Cell DifferentiationPosted 4 days ago
- Controlling Cell Culture pH in BioreactorsPosted 1 week ago
- The Impact of Aeration on Cell Culture OptimizationPosted 3 weeks ago
- Cool Tool – Novel universal titer boost and enhancer improves CHO cell protein production in small bioreactorsPosted 1 month ago
- The Dish’s Weekly Biotechnology News Wrap Up – September 16, 2016Posted 1 month ago
- Utilizing UVC LEDs in Biotech and Pharma – Paving the way to better instrument design and better manufacturing methodsPosted 1 month ago
- Synopsis: An Interview with Audrey Jia, former FDA CMC Reviewer for Biological ProductsPosted 1 month ago
- Predicting Differentiation and Characterizing Pluripotent Stem Cells Using Non-invasive Multi-analyte Luminex® AssaysPosted 1 month ago
- Particulates in Cell Therapy Products – An important issue for commercializationPosted 1 month ago
Recombinant LONG R3IGF‐1 and rTransferrin Improved Growth and Productivity of Two Suspension Chinese Hamster Ovary Cell lines
Jinghui Qian, Rina Gandhi, Ariane Marolewski
LONG®R3IGF‐1 is a human IGF‐1 analog containing a 13 amino acid N‐terminal extension and a mutation at position 3. It activates the Type 1 IGF receptor, which is responsible for growth‐promoting and protein synthesis effects in CHO cells. A common growth factor supplement used in CHO media, insulin, acts primarily through the IGF‐R.
LONG®R3IGF‐1 has previously been shown to increase CHO productivity. However, past characterization studies used primarily DMEM/F12 media. As serum‐free media development has progressed, media have become richer and more complex. To establish the effect of LONG®R3IGF‐1 in media that meet today’s industry standards, the effect of LONG®R3IGF‐1 on the productivity of two antibody‐expressing cell lines was compared to that of insulin and no growth factor supplemented media. The studies were carried out in TPP Tubespin50mL bioreactor tubes. Media with LONG®R3IGF‐1 gave superior titers versus no growth factor or insulin in several instances. In addition, it was demonstrated that combination of LONG®R3IGF‐1 and rTransferrin gave higher titer than commercial ITS (rInsulin, rTransferrin, Selenium) solution in several modern commercial media types.
LONG®R3IGF‐1 is used at low, 10 –100 ng/mL, concentrations in cell culture and is currently used in several commercial antibody manufacturing processes. It represents a regulatory‐friendly method of enhancing serum‐free cell culture performance. LONG®R3IGF‐1 should, therefore, be considered as a media supplement to further optimize a protein‐free process or to replace insulin in existing processes.